In Dec 2020, Huarui SmartLink completed an investment in Basel, Switzerland Molecular Diagnostics Platform through a Series C transaction, with committed capital of CHF 52M. The asset is currently valued at CHF 1.1B (2025 Valuation), and has become one of the firm's key tracked opportunities within its global multi-asset allocation framework.

Global public-health events increased the long-term investment value of rapid diagnostics, molecular testing, and laboratory automation platforms. Based on its assessment of industry trends, valuation levels, and market liquidity, the team continues to deepen research coverage and post-investment monitoring around this opportunity.

A partial stake sale to a European healthcare strategic buyer was completed in 2025, with the remaining shares targeted for further exit after 2026 if listing conditions improve. In parallel, the investment also improves early screening and diagnostic access while strengthening healthcare resilience and testing efficiency. This remains consistent with Huarui SmartLink's investment approach centered on long-term thinking, balanced risk-adjusted returns, and sustainable value creation.